Abstract
BackgroundGlycopyrronium bromide has recently been approved as a once daily maintenance inhalation therapy for moderate to severe chronic obstructive pulmonary disease (COPD). Efficacy and safety trial data have found rare cases of significant QT prolongation. To our knowledge, we describe the first case report of QT prolongation >600 ms with initiation of glycopyrronium bromide in a real world setting.Case presentationA 78-year-old female with moderate COPD recently started on glycopyrronium bromide, presented to Emergency Department (ED) with syncope. Her past medical history was significant for a left total mastectomy and she had been on Tamoxifen for 9 months. One day prior to her presentation, she had visited a naturopathic clinic for a vitamin infusion resulting in emesis. The following day she continued to feel dizzy and had a witnessed syncopal episode without any reported cardiac or neurological symptoms preceding the event or after regaining consciousness. In the emergency department, she reported dizziness and was found to be hypotensive. Her symptoms completely resolved with intravenous fluids. Lab work was normal however her electrocardiogram (ECG) demonstrated a QTc interval of 603 and 631 ms (Friderica and Bazett’s respectively) with a normal QT interval on her baseline ECG prior to initiating Tamoxifen. She was admitted to the Cardiology service for further work-up of QT prolongation. Her syncope was felt to be due to orthostatic hypotension and the QT prolongation secondary to medications, which were both discontinued during her admission. After 2 days, her QT interval normalized consistent with the half-life of Glycopyrronium bromide (13–57 h) compared to Tamoxifen (8–14 days).ConclusionGlycopyrronium bromide is guideline recommended as first line therapy for prevention of exacerbation in moderate to severe COPD however safety data had been limited to select populations. This case report highlights the need for future studies to identify high-risk populations at potential risk of life-threatening arrhythmias who may benefit from periodic ECG surveillance.
Highlights
Glycopyrronium bromide has recently been approved as a once daily maintenance inhalation therapy for moderate to severe chronic obstructive pulmonary disease (COPD)
Glycopyrronium bromide is guideline recommended as first line therapy for prevention of exacerbation in moderate to severe COPD safety data had been limited to select populations
This case report highlights the need for future studies to identify high-risk populations at potential risk of life-threatening arrhythmias who may benefit from periodic ECG surveillance
Summary
Glycopyrronium bromide is guideline recommended as first line therapy for prevention of exacerbation in moderate to severe COPD safety data in regards to QT prolongation has been limited to select populations. Ability of GB in moderate/ severe COPD vs placebo vs tiotropium Study type Randomized controlled trial (double blind) Size n = 1066. Inclusion criteria Males and females ≥40 years of age Smoking history of ≥10 pack-years GOLD moderate-to-severe COPD Post-bronchodilator FEV1 ≥30 and 470 ms for females, Symptomatic prostatic hyperplasia Bladder-neck obstruction Moderate/severe renal impairment Urinary retention Narrow-angle glaucoma Alpha-1 anti- trypsin deficiency Adverse reactions to inhaled anticholinergic agents, long- and short-acting alpha-agonists or Sympathomimetic amines Active pulmonary rehabilitation.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
